289 related articles for article (PubMed ID: 27010960)
1. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma.
Bournet B; Muscari F; Buscail C; Assenat E; Barthet M; Hammel P; Selves J; Guimbaud R; Cordelier P; Buscail L
Clin Transl Gastroenterol; 2016 Mar; 7(3):e157. PubMed ID: 27010960
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection.
Dai M; Jahanzaib R; Liao Y; Yao F; Li J; Teng X; Chen K; Cheng W
Front Oncol; 2022; 12():1074538. PubMed ID: 36582783
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer.
Ogura T; Yamao K; Hara K; Mizuno N; Hijioka S; Imaoka H; Sawaki A; Niwa Y; Tajika M; Kondo S; Tanaka T; Shimizu Y; Bhatia V; Higuchi K; Hosoda W; Yatabe Y
J Gastroenterol; 2013 May; 48(5):640-6. PubMed ID: 22983505
[TBL] [Abstract][Full Text] [Related]
4. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
5. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
[TBL] [Abstract][Full Text] [Related]
6. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
[TBL] [Abstract][Full Text] [Related]
7. Cobimetinib Plus Gemcitabine: An Active Combination in KRAS G12R-Mutated Pancreatic Ductal Adenocarcinoma Patients in Previously Treated and Failed Multiple Chemotherapies.
Ardalan B; Azqueta J; Sleeman D
J Pancreat Cancer; 2021; 7(1):65-70. PubMed ID: 34901697
[No Abstract] [Full Text] [Related]
8.
Shen H; Lundy J; Strickland AH; Harris M; Swan M; Desmond C; Jenkins BJ; Croagh D
Cells; 2022 Oct; 11(19):. PubMed ID: 36231137
[No Abstract] [Full Text] [Related]
9. Survival in ampullary cancer: potential role of different KRAS mutations.
Valsangkar NP; Ingkakul T; Correa-Gallego C; Mino-Kenudson M; Masia R; Lillemoe KD; Fernández-del Castillo C; Warshaw AL; Liss AS; Thayer SP
Surgery; 2015 Feb; 157(2):260-8. PubMed ID: 25616942
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and prognostic value of the
Yuan Y; Liu Y; Wu Y; Zhang J; Shen C; Zhang F; Wu C; Hu W
Int J Biol Markers; 2021 Jun; 36(2):33-39. PubMed ID: 34044655
[TBL] [Abstract][Full Text] [Related]
11. Not all mutations of
Li W; Liu Y; Cai S; Yang C; Lin Z; Zhou L; Liu L; Cheng X; Zeng W
Int J Clin Exp Pathol; 2019; 12(3):957-967. PubMed ID: 31933906
[TBL] [Abstract][Full Text] [Related]
12. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.
Cheng H; Luo G; Jin K; Fan Z; Huang Q; Gong Y; Xu J; Yu X; Liu C
Cancer Med; 2020 Mar; 9(6):2153-2159. PubMed ID: 32017404
[TBL] [Abstract][Full Text] [Related]
13. Impact of
Yousef A; Yousef M; Chowdhury S; Abdilleh K; Knafl M; Edelkamp P; Alfaro-Munoz K; Chacko R; Peterson J; Smaglo BG; Wolff RA; Pant S; Lee MS; Willis J; Overman M; Doss S; Matrisian L; Hurd MW; Snyder R; Katz MHG; Wang H; Maitra A; Shen JP; Zhao D
Res Sq; 2023 Aug; ():. PubMed ID: 37609177
[TBL] [Abstract][Full Text] [Related]
14. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma.
Yousef A; Yousef M; Chowdhury S; Abdilleh K; Knafl M; Edelkamp P; Alfaro-Munoz K; Chacko R; Peterson J; Smaglo BG; Wolff RA; Pant S; Lee MS; Willis J; Overman M; Doss S; Matrisian L; Hurd MW; Snyder R; Katz MHG; Wang H; Maitra A; Shen JP; Zhao D
NPJ Precis Oncol; 2024 Feb; 8(1):27. PubMed ID: 38310130
[TBL] [Abstract][Full Text] [Related]
15. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer.
Bournet B; Selves J; Grand D; Danjoux M; Hanoun N; Cordelier P; Buscail L
J Clin Gastroenterol; 2015 Jan; 49(1):50-6. PubMed ID: 24798941
[TBL] [Abstract][Full Text] [Related]
16. KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas.
Diehl AC; Hannan LM; Zhen DB; Coveler AL; King G; Cohen SA; Harris WP; Shankaran V; Wong KM; Green S; Ng N; Pillarisetty VG; Sham JG; Park JO; Reddi D; Konnick EQ; Pritchard CC; Baker K; Redman M; Chiorean EG
Oncologist; 2022 Dec; 27(12):1025-1033. PubMed ID: 36124727
[TBL] [Abstract][Full Text] [Related]
17. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis.
Bournet B; Souque A; Senesse P; Assenat E; Barthet M; Lesavre N; Aubert A; O'Toole D; Hammel P; Levy P; Ruszniewski P; Bouisson M; Escourrou J; Cordelier P; Buscail L
Endoscopy; 2009 Jun; 41(6):552-7. PubMed ID: 19533561
[TBL] [Abstract][Full Text] [Related]
18. Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer.
Bai B; Shan L; Xie B; Huang X; Mao W; Wang X; Wang D; Zhu H
Oncol Lett; 2018 Mar; 15(3):3161-3166. PubMed ID: 29435051
[No Abstract] [Full Text] [Related]
19. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
Nygaard AD; Garm Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Lung Cancer; 2013 Mar; 79(3):312-7. PubMed ID: 23238036
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Zhao D; Li H; Mambetsariev I; Mirzapoiazova T; Chen C; Fricke J; Kulkarni P; Villaflor V; Arvanitis L; Hamilton S; Afkhami M; Pillai R; Armstrong B; Erhunmwunsee L; Massarelli E; Sattler M; Amini A; Salgia R
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]